NPI registry status
Active
2026 NPPES data Gynecologic Oncology Physician NPI 1952797342 M.D.
Verify on CMS → Marla Scott, M.D.
Gynecologic Oncology Physician in Los Angeles, California.
This profile is drawn from the federal National Provider Identifier Registry (CMS NPPES), which lists more than 7 million U.S. healthcare providers - including 1,407 in Gynecologic Oncology Physician, and covers specialty classification, practice address, and Medicare Part D prescribing data when reported. According to CMS, every field reflects the provider's official federal registration, see our methodology.
Federal data, no proprietary rating.
We show these CMS records as-is - no composite score, no star rating, no editorial opinion layered on top.
Prescribing volume
347
Medicare Part D claims · 82 beneficiaries · Gynecologic Oncology Physician avg: 198
Generic prescribing
93%
generic claims · 7% brand-name · higher generic rates reduce patient out-of-pocket costs
Industry payments
$65.3
1 payments · CMS Open Payments (Sunshine Act)
Source: CMS Medicare Part D Prescriber Public Use File, 2024
What the federal data shows
Marla Scott, M.D. filed 347 Medicare Part D claims in 2024 as a Gynecologic Oncology Physician in Los Angeles, California, prescribing 93% generic.
- 347
- Part D claims, 2024
- 93%
- generic prescribing
- Likely
- board-certified (heuristic)
- ≥56th
- pct by Part D claim volume (lower-bound band)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) - no proprietary rating or editorial opinion is applied.
Federal trust snapshot
What official records show about Marla Scott, M.D.
Federal records show an active NPI with Medicare Part D prescribing activity — verifiable registry data, not a proprietary rating.
- Verified
NPI registry status
Active listing in the CMS National Provider Identifier Registry (NPI 1952797342), first enumerated 04/13/2015.
Source: CMS NPPES
- Reported
Medicare Part D participation
Filed 347 Medicare Part D prescription claims in the 2023 CMS public use file — indicates active Medicare prescribing participation.
Source: CMS Part D Prescriber PUF
- Reported
Board certification signal
Heuristic suggests board-certified status based on ABMS-eligible specialty taxonomy plus active CMS participation signals — not a direct ABMS verification.
- Reported
Hospital affiliations
1 CMS Care Compare hospital affiliation on record — practice footprint from the Doctors and Clinicians file.
Source: CMS Care Compare
- Reported
Industry payment transparency
$65.3 in reported industry payments (1 transfers) in 2024 under the federal Sunshine Act — disclosed transfers of value, not a quality rating.
Source: CMS Open Payments
- State context
State board disciplinary context
California statewide board action statistics are published annually — these figures describe aggregate state activity, not Marla Scott, M.D.'s individual license status. Verify directly with the state medical board.
Source: MBC annual report 2023
- Not in federal data
Individual sanction lookup
PlainDoctor does not publish per-provider disciplinary determinations. Confirm current license and any individual actions through the state medical board or FSMB verification service.
Source: State medical board / FSMB
This trust snapshot summarizes only what appears in federal CMS/NPPES public records. It is not a composite score, star rating, patient review, or clinical recommendation. PlainDoctor never fabricates reviews or AggregateRating schema.
CMS NPPES provider registry desk
NPI 1952797342 · Gynecologic Oncology Physician
NPI-10 · ENUM-MID · TAX-NARROW · RX-LIGHT · BOOK-THIN · PHOTO-ENUM
- NPI-10 1952797342
- ENUM-MID 2015
- TAX-NARROW 1,407
- RX-LIGHT 347
- BOOK-THIN 138 in California
- PHOTO-ENUM Lauren Scanlon, M.D. · 2015
Marla Scott, M.D.'s Medicare Part D volume vs every U.S. prescriber
Total Medicare Part D claims, 2024, across all CMS prescribers nationally
347 ≥ 56th percentile 56% of 1,416,883 prescribers are in lower value bands
Each bar is a band; taller bars hold more prescribers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
The percentile is a conservative 100-claim band: it counts only prescribers in lower claim-volume bands. Medicare Part D claim volume is activity context, not a quality measure or recommendation. See methodology § corpus placement.
Source CMS Medicare Part D Prescriber Public Use File · 2024
✓
Board certification likely (heuristic, not verified)
Marla Scott, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + 1 hospital affiliation - signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about Marla Scott, M.D.?
Quality data not reportedPrimary specialty
Gynecologic Oncology Physician
Medicare Part D claims
347 75% vs specialty avg
Specialty distribution in California
How Gynecologic Oncology Physician compares to other specialties among California providers
Board certification
Not published by CMS
CMS does not publish a per-provider board-certification field in NPPES. PlainDoctor does not have a reliable per-specialty certification rate to show for Gynecologic Oncology Physician. Verify directly:
How MIPS and board certification work
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
Practice Address
Provider Details
| NPI | 1952797342 |
|---|---|
| Specialty | Gynecologic Oncology Physician |
| Credentials | M.D. |
| Gender | Female |
| NPI Issued | 04/13/2015 |
Hospital and facility affiliations
Facilities where Marla Scott, M.D. bills Medicare from. Star ratings (1-5) are CMS Hospital Compare's "Hospital overall rating" - a composite of mortality, readmission, patient experience, safety, timely care, and efficient use of medical imaging measures. Source: CMS Care Compare.
Cedars-Sinai Medical Center
★★★★★ 5/5
West Hollywood, CA
Acute Care Hospitals
CMS CCN: 050625
Affiliations sourced from CMS Doctors and Clinicians National Downloadable File; hospital ratings from CMS Hospital General Information dataset (cross-referenced by facility name + state).
Industry payments received (2024) - CMS Open Payments transparency data
The federal Physician Payments Sunshine Act (part of the Affordable Care Act) requires drug and medical-device manufacturers + group purchasing organizations to publicly report payments and other transfers of value to physicians and teaching hospitals. The data below covers 2024 for Marla Scott, M.D.. Source: openpaymentsdata.cms.gov.
Total received
$65
Largest payer
AstraZeneca Pharmaceuticals LP
Most common payment type
Food and Beverage
Industry payments are not necessarily indicators of bias, they include research funding, consulting fees for evidence-based work, royalties for inventions, food at conferences, and similar items. The disclosure exists for transparency. Read our methodology for how we interpret this data.
License & disciplinary context - California MBC 2023 annual report
Aggregate state board data only, NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~150K California medical licensees in 2023 - they are NOT specific to Marla Scott, M.D.. To verify Marla Scott, M.D.'s current license status, search the MBC public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
576
Total board actions, California 2023
Across 556 cases
3.84
Actions per 1,000 licensees
California statewide rate
probation
Most common action type
186 cases
MBC publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the California disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Generic-heavy
Marla Scott, M.D. - brand share 7.0%
Gynecologic Oncology Physician average
7% brand-name claims vs 93% generic, on 347 2024 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2024.
347
Total Claims
$12K
Total Drug Cost
82
Medicare Beneficiaries
Prescribing Breakdown
- 30-Day Fills
- 467.333
- Total Day Supply
- 9,436
- Brand vs Generic
- 7% brand / 93% generic
- Brand Drug Cost
- $7K
- Generic Drug Cost
- $6K
- Opioid Claims
- 50 (14.4% rate)
- Antibiotic Claims
- 15
Patient Demographics
- Average Patient Age
- 72.3 years
- Avg HCC Risk Score
- 1.52
- Gender Split
- 100% female / 0% male
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2024. Based on Medicare Part D data only.
What Marla Scott, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2024
- Dexamethasone
Dexamethasone
39 claims
- Oxycodone Hcl
Oxycodone Hcl
37 claims
- Ibuprofen
Ibuprofen
27 claims
- Prochlorperazine M…
Prochlorperazine Maleate
26 claims
- Ondansetron Odt
Ondansetron Odt
21 claims
- Estradiol
Estradiol
19 claims
- Gabapentin
Gabapentin
18 claims
- Clobetasol Propion… 13
Clobetasol Propionate
13 claims
| Drug | Claims |
|---|---|
| Dexamethasone | 39 |
| Oxycodone Hcl | 37 |
| Ibuprofen | 27 |
| Prochlorperazine Maleate | 26 |
| Ondansetron Odt Ondansetron | 21 |
| Estradiol | 19 |
| Gabapentin | 18 |
| Clobetasol Propionate | 13 |
| Lorazepam | 12 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 11 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Gynecologic Oncology Physician Overview
How Marla Scott, M.D. fits within the Gynecologic Oncology Physician landscape nationally.
1,407
Gynecologic Oncology Physician Providers in US
49
States with Gynecologic Oncology Physician
198
Avg Claims per Provider
Marla Scott, M.D.'s 347 claims are above the specialty average of 198.
Nationwide Gynecologic Oncology Physician peers with similar MIPS or enrollment year
Two federal-record peer sets for Scott, both outside California so the neighborhoods are not geographic containment.
Same NPPES enumeration year (2015)
Same-specialty clinicians who entered the NPI registry in the same calendar year, outside this state.
Nearby Gynecologic Oncology Physician Providers in California
Other clinicians with the same primary specialty enrolled in California, drawn from the same CMS NPPES roster as Scott.
One of 138 Gynecologic Oncology Physician providers enrolled in California, 5 are shown here.
Dr. Lisa Abaid
M.D., M.P.H.
Newport Beach, CA
Dr. Alireza Abidi
M.D.
Sacramento, CA
Dr. Federico Alva
M.D.
Northridge, CA
Dr. Edwin Alvarez
M.D.
Sacramento, CA
Dr. Kristen Anderson
M.D., PH.D.
Moreno Valley, CA
Compare Gynecologic Oncology Physician nationally: see state-by-state distribution →
Frequently Asked Questions
What is Marla Scott, M.D.'s specialty? ▼
Marla Scott, M.D. specializes in Gynecologic Oncology Physician and practices in Los Angeles, California. Credentials: M.D..
How much does Marla Scott, M.D. prescribe under Medicare Part D? ▼
In 2024, Marla Scott, M.D. wrote 347 Medicare Part D claims totaling $12K in drug costs for 82 beneficiaries.
Where is Marla Scott, M.D. located? ▼
Marla Scott, M.D. is located at 127 S SAN VICENTE BLVD FL 7, Los Angeles, CA, 90048. Phone: (310) 423-5800.
What is Marla Scott, M.D.'s NPI number? ▼
Marla Scott, M.D.'s National Provider Identifier (NPI) is 1952797342, issued on 04/13/2015.
Does Marla Scott, M.D. prescribe more brand-name or generic drugs? ▼
Marla Scott, M.D.'s prescribing is 7% brand-name and 93% generic drugs by claim count, with $7K in brand drug costs.
Does Marla Scott, M.D. prescribe opioids? ▼
Yes, Marla Scott, M.D. had 50 opioid claims in 2024 with an opioid prescribing rate of 14.4%.
How many Gynecologic Oncology Physician providers are there in the US? ▼
There are 1,407 Gynecologic Oncology Physician providers across 49 states in the US. The average Gynecologic Oncology Physician provider writes 198 Medicare Part D claims per year.
What drugs does Marla Scott, M.D. prescribe most often? ▼
Based on 2024 Medicare Part D data, Marla Scott, M.D.'s most frequently prescribed drugs include Dexamethasone, Oxycodone Hcl, Ibuprofen. This reflects Medicare Part D prescriptions only and does not include commercial insurance or other payer types.
Does Marla Scott, M.D. accept Medicare? ▼
Marla Scott, M.D. appears in CMS Medicare data with 347 Part D claims and 82 Medicare beneficiaries in 2024. Contact the provider's office directly to confirm current Medicare enrollment and accepted plans.
How can I verify Marla Scott, M.D.'s credentials? ▼
Marla Scott, M.D.'s NPI is 1952797342 with credentials M.D.. You can verify this through the NPPES NPI Registry, check state medical board records, and confirm board certification through the ABMS or AOA.
Data Sources
View source datasets and methodology notes
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2024). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of August 2026 (NPPES) / 2024 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology
Every figure on PlainDoctor is rendered directly from the federal CMS NPPES registry, Medicare Part D, MIPS, and Open Payments records, no number is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.